Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Scirica MD

Benjamin Morgan Scirica MD

Senior Physician and Director, Innovation, Cardiovascular Division, Brigham and Women's Hospital; Professor of Medicine, Harvard Medical School; Senior Investigator, TIMI Study Group, Boston, Massachusetts

Dr. Benjamin Scirica is a senior physician and Director of Innovation in the Cardiovascular Division at Brigham and Women's Hospital and Professor of Medicine at Harvard Medical School. He is a Senior Investigator at the TIMI Study Group (an academic research organization based at Brigham and Women's Hospital that has performed over 75 clinical trials in cardiometabolic diseases).

His research interests center on the risk stratification, management, and the identifation of novel therapies to improve outcomes in patients with acute coronary syndromes and cardiometabolic disorders. 

Dr. Scirica has authored or co-authored over 200 peer-reviewed articles and is a reviewer for multiple journals, including The New England Journal of Medicine, JAMA, The Lancet, Circulation, and Journal of the American College of Cardiology (JACC).

Disclosures

  • Institutional research support to Brigham and Women’s Hospital from: Amgen; Better Therapeutics; Boehringer Ingelheim; Merck; Novo Nordisk; Pfizer; Verve Therapeutics
  • Consulting fees from: AbbVie (DSMB); Amgen; AstraZeneca (DSMB); Bayer; Boehringer Ingelheim (DSMB); Elsevier Practice Update Cardiology; Hanmi (DSMB); Lexeo (DSMB); Novo Nordisk; Verve Therapeutics; and equity in Health [at] Scale; Arboretum Lifescience

Recent Contributions to PracticeUpdate:

  1. Aleglitazar Effect on CV Outcomes in Type 2 Diabetes
  2. Comparison of ACC/AHA, ATP III, and ESC Guidelines for CVD Prevention
  3. Proportion of US Adults Affected by the New Hypertension Guideline
  4. Evolocumab in Hyperlipidemia
  5. Validation of Atherosclerotic CVD Risk Equations
  6. Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin
  7. ACC 2014: Late-Breaking Trials—Ben Scirica, MD
  8. Smoking, CAD, and Prognosis of Patients With Non–ST-Segment Elevation ACS
  9. No Incremental Benefit Seen With Ezetimibe
  10. PCI in Patients With Stable Obstructive Coronary Artery Disease and Myocardial Ischemia

Most Read This Week

Recently Updated